{"preliminary_commentary":{"by_channel":{"x_thread":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"STARLiT","nct_id":"NCT06574880","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=starlit-nct06574880. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"STARLiT","arms":[{"description":"* Lu-PSMA-617: 7.4GBq intravenous infusion once with cycle 1, followed by 7.4GBq cycle 2 that is delivered 6 weeks after SBRT , and potentially 7.4GBq cycle #3 delivered 6 weeks after cycle #2 pending dose escalation\n* Radiation therapy: 5 fractions to prostate and elective nodal irradiation, SBRT, delivered 6 weeks after cycle 1 of 177Lu-PSMA-617","label":"Lu-PSMA-617 + SBRT","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-03-01","type":"ESTIMATED"},"conditions":["Malignant Neoplasm of Prostate","Locally Advanced Prostate Cancer"],"enrollment":{"count":45,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Lu-PSMA-617","otherNames":["Pluvicto"],"type":"DRUG"},{"name":"5-fraction Stereotactic Body Radiation Therapy (SBRT)","otherNames":["SBRT"],"type":"RADIATION"}],"last_update":"2026-05-26","lead_sponsor":"Angela Y. Jia, MD PhD","official_title":"STARLiT: STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer: A Phase I/II Trial","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-09-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase I: Maximum tolerated dose (MTD) of Lu-PSMA-617","timeFrame":"4 weeks after final dose of treatment (treatment expected to last up to six months)"},{"measure":"Phase II: Androgen deprivation therapy (ADT)-free survival","timeFrame":"3 years post treatment"}],"references":[],"start_date":{"date":"2025-05-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT06574880"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/starlit-nct06574880"}